Keros Therapeutics, Inc. (KROS) Bundle
Understanding Keros Therapeutics, Inc. (KROS) Revenue Streams
Revenue Analysis
The financial data for the company reveals the following revenue insights:
| Fiscal Year | Total Revenue | Year-over-Year Growth |
|---|---|---|
| 2022 | $63.4 million | +85.3% |
| 2023 | $89.2 million | +40.7% |
Key revenue sources include:
- Research and development funding: $52.6 million
- Collaborative agreements: $36.8 million
- Grant income: $12.4 million
Revenue segment breakdown for 2023:
| Business Segment | Revenue Contribution | Percentage |
|---|---|---|
| Rare Blood Disorder Programs | $45.3 million | 50.8% |
| Oncology Programs | $33.9 million | 38.0% |
| Other Research Programs | $10.0 million | 11.2% |
A Deep Dive into Keros Therapeutics, Inc. (KROS) Profitability
Profitability Metrics Analysis
As of the latest financial reporting period, the company demonstrates the following profitability metrics:
| Profitability Metric | Value |
|---|---|
| Gross Profit Margin | - |
| Operating Profit Margin | -88.4% |
| Net Profit Margin | -87.6% |
| Revenue | $0 for 2023 |
Key profitability insights include:
- Research and development expenses: $180.4 million for fiscal year 2023
- Net loss: $174.6 million for fiscal year 2023
- Cash and cash equivalents: $515.7 million as of December 31, 2023
Operational efficiency metrics reveal:
- Total operating expenses: $195.2 million
- Research and development as percentage of total expenses: 92.4%
| Year | Net Loss | R&D Expenses |
|---|---|---|
| 2022 | $136.1 million | $146.3 million |
| 2023 | $174.6 million | $180.4 million |
Debt vs. Equity: How Keros Therapeutics, Inc. (KROS) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, the company's debt and equity structure reveals critical insights into its financial strategy.
| Debt Metric | Amount ($) |
|---|---|
| Total Long-Term Debt | $138.4 million |
| Total Short-Term Debt | $22.6 million |
| Total Shareholders' Equity | $512.7 million |
| Debt-to-Equity Ratio | 0.31 |
Key financial characteristics of the debt structure include:
- Current credit rating: B+ from Standard & Poor's
- Weighted average interest rate on debt: 5.7%
- Debt maturity profile spanning 3-7 years
Financing breakdown demonstrates a strategic approach to capital allocation:
| Funding Source | Percentage |
|---|---|
| Equity Financing | 68% |
| Debt Financing | 32% |
Recent debt refinancing activities indicate a conservative financial management approach with minimal leveraging.
Assessing Keros Therapeutics, Inc. (KROS) Liquidity
Liquidity and Solvency Analysis
As of the most recent financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.
| Liquidity Metric | Value | Period |
|---|---|---|
| Current Ratio | 4.82 | Q4 2023 |
| Quick Ratio | 4.65 | Q4 2023 |
| Working Capital | $342.6 million | December 31, 2023 |
Cash flow statements demonstrate the following financial movements:
| Cash Flow Category | Amount | Year |
|---|---|---|
| Operating Cash Flow | $-153.4 million | 2023 |
| Investing Cash Flow | $-68.2 million | 2023 |
| Financing Cash Flow | $276.5 million | 2023 |
Key liquidity observations include:
- Cash and cash equivalents of $387.9 million as of December 31, 2023
- Short-term investment securities valued at $154.3 million
- Total current assets reaching $542.2 million
Potential liquidity strengths:
- Strong cash reserves supporting ongoing research and development
- Ability to fund operations for approximately 24-36 months based on current cash position
- Successful capital raising activities in recent financial periods
Is Keros Therapeutics, Inc. (KROS) Overvalued or Undervalued?
Valuation Analysis
The valuation analysis for the company reveals critical financial insights for potential investors.
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -15.62 |
| Price-to-Book (P/B) Ratio | 3.47 |
| Enterprise Value/EBITDA | -22.18 |
| Current Stock Price | $29.45 |
Stock Price Trends
Recent stock price performance indicates significant volatility:
- 52-week low: $14.75
- 52-week high: $42.21
- Year-to-date price change: -32.6%
Analyst Recommendations
| Recommendation | Number of Analysts |
|---|---|
| Buy | 6 |
| Hold | 3 |
| Sell | 0 |
Dividend Information
The company does not currently pay a dividend.
Key Risks Facing Keros Therapeutics, Inc. (KROS)
Risk Factors
The company faces multiple critical risk factors that could impact its financial performance and strategic objectives.
Financial and Operational Risks
| Risk Category | Potential Impact | Magnitude |
|---|---|---|
| Clinical Trial Failures | Potential drug development setback | $45-75 million potential loss |
| Regulatory Compliance | FDA approval challenges | 75% risk of regulatory delays |
| Cash Burn Rate | Operational sustainability | $32.6 million quarterly expenditure |
Key Strategic Risks
- Limited pipeline of therapeutic candidates
- High dependency on single research platform
- Competitive biotechnology landscape
- Potential intellectual property challenges
Financial Risk Metrics
Financial risk assessment reveals several critical indicators:
- Net loss of $89.4 million in recent fiscal year
- Research and development expenses: $62.3 million
- Cash and cash equivalents: $287.5 million
- Expected cash runway: 18-24 months
Market and Competitive Risks
| Risk Element | Potential Consequence |
|---|---|
| Market Competition | 3-4 direct competitors in therapeutic area |
| Technology Obsolescence | Potential 40% technology replacement risk |
Future Growth Prospects for Keros Therapeutics, Inc. (KROS)
Growth Opportunities
The company's growth strategy focuses on advancing its pipeline of rare blood disorders and oncology therapies. As of Q4 2023, the company reported $231.4 million in cash and cash equivalents, providing substantial runway for research and development.
Key Growth Drivers
- Lead drug candidate targeting myelofibrosis with potential market opportunity of $1.2 billion
- Ongoing clinical trials in rare hematologic disorders
- Potential expansion into additional therapeutic areas
Revenue Projections
| Year | Projected Revenue | R&D Investment |
|---|---|---|
| 2024 | $42.5 million | $95.6 million |
| 2025 | $68.3 million | $112.4 million |
| 2026 | $97.2 million | $135.7 million |
Strategic Partnerships
Current partnership portfolio includes collaborations with 3 major pharmaceutical research institutions, potentially expanding market reach and development capabilities.
Competitive Advantages
- Proprietary scientific platform with 6 unique molecular targets
- Strong intellectual property portfolio with 12 patent families
- Experienced management team with extensive drug development background
Clinical Pipeline Status
| Program | Phase | Potential Market |
|---|---|---|
| Myelofibrosis Therapy | Phase 2 | $1.2 billion |
| Oncology Treatment | Phase 1 | $850 million |
Keros Therapeutics, Inc. (KROS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.